Loking at the selloff and the volume between ACHN and IDIX, I suspect that ACHN's lead compound a PI drug called ACH-1625 will emerge as the leader in the class of Hep C treatments. ACHN could rebound quite a bit as the thinking seems to be in a shifting process towards the favor of ACHN. think buyout at about $35 a share.
A buddy and a long time long in ViroPharma(VPHM) has a bunch of YMI for 56 cents a piece. Of course I was also in VPHM for quite some years. Sold them all @14 and change and plowed that money into ACHN. Once a while I still stop by and congratulate the stout longs. We still have our own private board to discuss without having to weed out nonsense and fud which are rampant in Yahoo Finance Boards!LOL. ViroPharma disappointed a lot of Folks with the failure in their HepC compound(HCV-796) partnered then with ex-Wyatt and later the PIII failure of Maribavir. If it wasn't for the cash cow Vancomycin and now Cinryze for treating HAE; their pps will never attain the level of today. All The Best!